0001411690-14-000001.txt : 20140108 0001411690-14-000001.hdr.sgml : 20140108 20140107184433 ACCESSION NUMBER: 0001411690-14-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140108 DATE AS OF CHANGE: 20140107 EFFECTIVENESS DATE: 20140108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNano Genomics, Inc CENTRAL INDEX KEY: 0001411690 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-209492 FILM NUMBER: 14514673 BUSINESS ADDRESS: STREET 1: 9640 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 888-7600 MAIL ADDRESS: STREET 1: 9640 TOWNE CENTRE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BioNanomatrix Inc DATE OF NAME CHANGE: 20070906 D 1 primary_doc.xml X0707 D LIVE 0001411690 BioNano Genomics, Inc 9640 TOWNE CENTRE DRIVE, Suite 100 SAN DIEGO CA CALIFORNIA 92121 (858) 888-7600 DELAWARE BioNanomatrix, LLC BioNanomatrix Inc Corporation true R. Erik Holmlin c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Executive Officer Director David L. Barker c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Director Brian Halak c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Director Albert A. Luderer c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Director Tracy Warren c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Director Han Cao c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Executive Officer Lynne Rollins c/o BioNano Genomics, Inc. 9640 Towne Centre Drive, Suite 100 San Diego CA CALIFORNIA 92121 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2013-12-11 false true true true Securities offered consist of a warrant exercisable for shares of convertible preferred stock, the convertible preferred stock issuable upon exercise of the warrant and the common stock underlying the convertible preferred stock. false 0 15000 15000 0 The amount listed above is the amount receivable upon the exercise of a warrant to purchase shares of convertible preferred stock. Such warrant has not yet been exercised. false 1 0 0 0 false BioNano Genomics, Inc Erik Holmlin, Ph.D. Erik Holmlin, Ph.D. President and CEO 2014-01-06